Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms (NCT05623787)
Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Recurrence in Patients With High-risk Colorectal and Appendiceal Neoplasms : a Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases PM. It has been demonstrated to be superior to CT for patients with known peritoneal disease from colorectal and gynaecological malignancies as a staging tool for cytoreductive surgery. It was also demonstrated to be superior for the detection of PM for gastric cancer patients otherwise considered with a resectable tumor. However, the literature is scarce on the role of DWI/MRI in the detection of peritoneal recurrence for patients with high-risk features, either colorectal cancer (CRC) or appendiceal neoplasms (AN). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT and diagnostic laparoscopy for detection of PM in the follow-up of patients presenting with CRC or AN and high-risk features for peritoneal recurrence and evaluate how it correlates with intraoperative findings.
Who can join: Review the eligibility criteria below.
Location: CIUSSS de l'Est-de-l'Île-de-Montréal — Montreal, Quebec
Age range: 18 Years
🧪 Interventions in This Study
- Whole-body diffusion-weighted magnetic resonance imaging (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- CIUSSS de l'Est-de-l'Île-de-Montréal — Montreal, Quebec
- CHU de Québec — Québec, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Peritoneal Carcinomatosis
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors — Tampa, Florida
- Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC — Lexington, Kentucky
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery — Tampa, Florida
- Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC) — Montreal, Quebec
- Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis — Orange, California
Explore by condition: All Peritoneal Carcinomatosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.